Most FDA-approved drugs reach patients with nothing more than standard prescribing information and, where relevant, a boxed warning. A smaller group of drugs, where the FDA has determined the risks need active, structural safeguards beyond a warning label, get something more: a Risk Evaluation and Mitigation Strategy, or REMS.
What a REMS Actually Requires
A REMS is a formal safety program the FDA can require as a condition of approval when a drug's benefits are judged to outweigh its risks only if specific additional safeguards are in place. Depending on the drug, a REMS can include a Medication Guide patients must receive, a communication plan to inform healthcare providers about serious risks, or, for the strictest category, Elements to Assure Safe Use (ETASU). ETASU can require prescribers and pharmacies to complete specific training and become certified, require patients to enroll in a registry, mandate specific lab monitoring before each dose, or restrict dispensing to certain certified healthcare settings. The best-known examples outside the peptide world are the iPLEDGE program for isotretinoin and the REMS requirements tied to clozapine and many opioid products.
Why Most Peptide Drugs Don't Have One
For the large majority of FDA-approved peptide drugs covered on this site, including semaglutide, tirzepatide, liraglutide, teriparatide, and dulaglutide, the FDA has determined that a boxed warning and standard prescribing information are sufficient to manage their known risks. That's a specific regulatory judgment about risk-versus-benefit and feasible mitigation, not a statement that these drugs are risk-free; several of them do carry boxed warnings, such as the thyroid C-cell tumor warning on GLP-1 drugs discussed elsewhere on this site, without needing the additional structural controls of a REMS.
A Peptide Drug That Does Have One
Metreleptin (Myalept), the FDA-approved leptin analog for generalized lipodystrophy discussed in this site's guide to appetite-regulating hormones, is a clear example of a peptide drug that does carry a REMS. Myalept's REMS exists because of the risk that patients can develop anti-metreleptin antibodies that neutralize the drug's effect and, more seriously, cross-react with the body's own natural leptin, which has been linked to severe infections, plus a boxed warning for T-cell lymphoma and a risk of triggering or worsening autoimmune disease. Under its REMS, prescribers and pharmacies must be specifically certified to prescribe and dispense the drug, rather than it being available at any pharmacy that fills a standard prescription.
How to Tell Whether a Drug Has One
The FDA maintains a public, searchable database of all currently approved REMS programs on its website, and a drug's own FDA-approved prescribing information will explicitly state whether a REMS applies and summarize its requirements. This is a more reliable way to check than assuming based on how serious a drug's boxed warning sounds, since, as the comparison between GLP-1 drugs and Myalept shows, having a boxed warning and needing a REMS are related but genuinely separate regulatory determinations.
The Bottom Line
A REMS isn't a general marker of "this drug is riskier than that one"; it's a specific regulatory tool the FDA applies only when it concludes a drug's risk can't be adequately managed through labeling alone. Among the many peptide drugs this site covers, that conclusion has so far been reached for a narrow set of cases like metreleptin, not for the GLP-1 drugs most readers are likely searching for.